Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHRP-6
Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
One of the original synthetic growth hormone secretagogues, developed in the 1980s. A hexapeptide that strongly stimulates GH release through ghrelin receptor activation. Historically significant as the compound that led to the discovery of the ghrelin receptor and the development of the entire GHS drug class.
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release. Also stimulates appetite significantly through central ghrelin receptor activation — more so than most other GHS peptides. Increases IGF-1 levels downstream of GH release.
Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.
- Growth hormone optimization
- Muscle recovery and growth
- Fat loss
- Appetite stimulation (useful in wasting conditions)
- Anti-aging protocols
- Growth hormone deficiency treatment
- Anti-aging protocols
- Improved sleep
- Body composition improvement
- Recovery enhancement
- Significant appetite stimulation (can undermine fat loss goals)
- Cortisol and prolactin elevation
- Water retention
- Desensitization with frequent dosing
- Tingling and numbness
- Limited long-term human safety data
- Injection site reactions (redness, swelling)
- Headaches
- Flushing
- Dizziness
- Generally well-tolerated in clinical studies
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription. Often used in combination with GHRH analogs like CJC-1295.
Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
- Growth hormone-releasing peptides and their analogs
1998 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.